Planta Medica Letters 2015; 2(01): e35-e38
DOI: 10.1055/s-0035-1557830
Letter
Georg Thieme Verlag KG Stuttgart · New York

Leucas mollissima, a Source of Bioactive Compounds with Antimalarial and Antimycobacterium Activities

Ashish A. Chinchansure
1  Division of Organic Chemistry, CSIR-National Chemical Laboratory, Pune, India
,
Manisha Arkile
2  Combi-Chem Bio-Resource Centre, CSIR-National Chemical Laboratory, Pune, India
,
Anurag Shukla
3  Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune, India
,
Dhanasekaran Shanmugam
3  Biochemical Sciences Division, CSIR-National Chemical Laboratory, Pune, India
,
Dhiman Sarkar
2  Combi-Chem Bio-Resource Centre, CSIR-National Chemical Laboratory, Pune, India
,
Swati P. Joshi
1  Division of Organic Chemistry, CSIR-National Chemical Laboratory, Pune, India
› Author Affiliations
Further Information

Publication History

received 27 February 2015
revised 30 June 2015

accepted 09 July 2015

Publication Date:
04 September 2015 (online)

Abstract

A phytochemical investigation of the acetone extract from the aerial parts of Leucas mollissima afforded one new (−)epi-marmelo lactone, (2 S, 4R, 6 S)-2,6-dimethyl-6 hydroxy-7-ene-4-olide (1), along with five known compounds, schensianol A (2), vanillin (3), β-hydroxy propiovanillone (4), lanost-9(11),25-diene-3β,24β-diol (5), and lanost-9(11),23E(24)-diene-3β,25-diol (6). Similarly, an investigation of the methanol extract of the aerial parts of L. mollissima resulted in the isolation of three known compounds, (+)-syringaresinol (7), anisofolin A (8), and apigenin 7-O-β-D(− 6′′-p-E-coumaroyl)-glucoside (9). Structure elucidation of the isolated compounds was carried out using detailed analysis of 1D and 2D nuclear magnetic resonance. All compounds were evaluated for antimalarial activity against Plasmodium falciparum (3D7) and for antimycobacterium activity against Mycobacterium tuberculosis H37Ra and Mycobacterium bovis. Compound 8 was found to have promising antimalarial activity (IC50 4.39 ± 0.25 µM), promising antimycobacterium activity [IC50 4.50 ± 0.75 µM (3.31 µg/mL)] against M. tuberculosis H37Ra and at 100 µg/mL, showed 55.6 % inhibition of M. bovis. Compound 9 showed moderate inhibition of P. falciparum growth (35 % inhibition at 10 µM) with respect to the positive control atovaquone and 67.4 % inhibition against M. bovis at 100 µg/mL with respect to the positive control rifampicin.

Supporting Information